



Edition: BP 2025 (Ph. Eur. 11.6 update)

## Desmopressin Intranasal Solution

### [General Notices](#)

### Action and use

Vasopressin analogue; treatment of diabetes insipidus.

### DEFINITION

Desmopressin Intranasal Solution is a solution of Desmopressin containing suitable buffering agents and preservatives.

*The intranasal solution complies with the requirements stated under Nasal Preparations and with the following requirements.*

### Content of desmopressin, $C_{46}H_{64}N_{14}O_{12}S_2$

90.0 to 110.0% of the stated amount of the peptide.

### CHARACTERISTICS

A colourless solution.

### IDENTIFICATION

In the Assay, the principal peak in the chromatogram obtained with solution (1) corresponds to that in the chromatogram obtained with solution (2).

### TESTS

#### Acidity

pH, 3.5 to 5.5, [Appendix V L](#).

#### Related substances

Carry out the method for [liquid chromatography, Appendix III D](#), using the following solutions and the *normalisation procedure*.

- (1) Dilute a volume of the intranasal solution in [water](#) to produce a solution containing 0.0025% w/v of the peptide.
- (2) Dissolve the contents of a vial of [desmopressin impurity standard BPCRS](#) in 2 mL of [water](#).

CHROMATOGRAPHIC CONDITIONS

- Use a stainless steel column (12 cm × 4.0 mm) packed with [octadecylsilyl silica gel for chromatography](#) (5 µm) (Nucleosil C18 is suitable).
- Use gradient elution and the mobile phase described below.
- Use a flow rate of 1.5 mL per minute.
- Use an ambient column temperature.
- Use a detection wavelength of 220 nm.
- Inject 200 µL of each solution.

#### MOBILE PHASE

*Mobile phase A* 0.067M mixed phosphate buffer solution, pH 7.0.

*Mobile phase B* 10 volumes of [acetonitrile for chromatography](#) and 10 volumes of mobile phase A.

Time (Minutes)	Mobile phase A%	Mobile phase B%	Comment
0-4	76	24	isocratic
4-18	76→58	24→42	linear gradient
18-35	58→48	42→52	linear gradient
35-40	48→76	52→24	linear gradient
40-50	76	24	re-equilibration

Using the prescribed conditions the retention time of [4- L -glutamic acid]desmopressin is about 14 minutes and the retention time of desmopressin is about 15 minutes.

#### SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (2), the [resolution](#) between the two principal peaks is at least 3.4;

the peak due to desmopressin is clearly separated from the peak due to the antimicrobial preservative stated on the label.

#### LIMITS

In the chromatogram obtained with solution (1):

the area of any [secondary peak](#) is not more than 4.0%.

the total area of any such peaks is not more than 5.0%.

Disregard any peak due to the solvent, any antimicrobial preservative stated on the label and any peak with an area less than 0.3%.

## ASSAY

Carry out the method for [liquid chromatography, Appendix III D](#), using the following solutions.

- Dilute a volume of the intranasal solution in [water](#) to produce a solution containing 0.0025% w/v of the peptide.
- 0.0025% w/v of [desmopressin BPCRS](#) in [water](#).
- Dissolve the contents of a vial of [desmopressin impurity standard BPCRS](#) in 2 mL of [water](#).

#### CHROMATOGRAPHIC CONDITIONS

- Use a stainless steel column (12 cm × 4.0 mm) packed with [octadecylsilyl silica gel for chromatography](#) (5 µm) (Nucleosil C18 is suitable).
- Use isocratic elution and the mobile phase described below.
- Use a flow rate of 2 mL per minute.
- Use an ambient column temperature.
- Use a detection wavelength of 220 nm.

(f) Inject 200  $\mu$ L of each solution.

#### MOBILE PHASE

A mixture of 2 volumes of [acetonitrile for chromatography](#) and 8 volumes of 0.067M mixed phosphate buffer solution, pH 7.0.

#### SYSTEM SUITABILITY

The test is not valid unless:

in the chromatogram obtained with solution (3), the [resolution](#) between the two principal peaks is at least 2.8;

the peak due to desmopressin is clearly separated from the peak due to the antimicrobial preservative stated on the label.

The retention time of desmopressin is about 5 minutes. If necessary adjust the concentration of [acetonitrile](#) in the mobile phase to obtain the correct retention time and [resolution](#).

#### DETERMINATION OF CONTENT

Calculate the content of  $C_{46}H_{64}N_{14}O_{12}S_2$  in the intranasal solution from the chromatograms obtained and from the declared content of  $C_{46}H_{64}N_{14}O_{12}S_2$  in [desmopressin BPCRS](#).

## STORAGE

Desmopressin Intranasal Solution should be protected from light and stored at a temperature of 2° to 8°, unless otherwise justified and authorised.